180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, is growing its patent portfolio. The company announced that the Yissum Research Development Company of the Hebrew University has received grants of two new patents, one in the United States (19 Oct 2021, patent no US 11,149,014) and one in Canada (26 Oct 2021, patent no CA 2,944,837). Through its license agreement with the Yissum Research Development Company, 180 Life Sciences has exclusive rights to the use of these patents. According to the company, the patents relate to a method for treating chronic pain or associated conditions/symptoms with novel compositions that include certain phenyl substituted cyclohexenyl compounds related to cannabidiol (“CBD”). “Our priority indication is residual pain in patients with established rheumatoid arthritis (‘RA’), who have not responded adequately to standard-of-care therapies,” said 180 Life Sciences CEO Dr. James Woody in the press release. “RA is estimated to affect 1% of the global population, and anti-TNF biologics have been shown in many studies to be very effective in treating joint inflammation in 60–70% of cases. However, a significant number of patients still require an alternative to what is currently available. Working through different mechanisms to commonly used anti-inflammatory RA medications, we believe that SCAs could offer a complementary therapeutic strategy for addressing the unremitting pain that disables many patients.”
To view the full press release, visit
https://ibn.fm/kslKk
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit
www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at
https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.